Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes

Experimental and Clinical Endocrinology and Diabetes

Volumn 106, Issue 1, 1998, Pages 79-84

  Hubler A ^a   Abendroth, K ^a   Keiner, T ^a   Stocker W ^b   Kauf, E ^a   Hein, G ^a   Stein, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Institute of Experimental Immunology   (Germany)

Author keywords

Autoantobodies against lipocytes; Insulin growth factor dysregulation; Lawrence syndrome; Lipoatrophic diabetes mellitus

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GROWTH FACTOR; INSULIN; LIVER ENZYME; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACANTHOSIS NIGRICANS; ADIPOCYTE MEMBRANE; ADIPOSE TISSUE; ADULT; ARTICLE; CASE REPORT; FATTY LIVER; GLOMERULOPATHY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; LIPOATROPHIC DIABETES MELLITUS; LIPODYSTROPHY; MALE; MUSCLE STRENGTH; MYALGIA; NEURALGIA; PATHOGENESIS; PRIORITY JOURNAL; STELLATE CELL; SUBCUTANEOUS TISSUE; WEIGHT REDUCTION;

EID: 0031931291     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211955     Document Type: Article

References (33)

1. Bach MA, Chin E, Bondy C: The Effects of Subcutaneous Insulin-Like Growth Factor-I Infusion in Insulin-Dependent Diabetes Mellitus. J Clin Endocrinol Metab 79: 1040-1045, 1994
2. Baxter RC: The somatomedins: Insulin-like growth factors. Adv Clin Chem 25: 49-115, 1986
3. Behringer RR, Lewin TM, Quaife CJ, Palmiter RD, Brinster RL, D'Ercole AJ: Expression of Insulin-Like Growth Factor I Stimulates Normal Somatic Growth in Growth Hormone-Deficient Transgenic Mice. Endocrinology. 127: 1033-1040, 1990
4. Blum WF, Ranke MB, Bierich JR: A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I, Acta Endocrin. 118, 374-380, 1988
5. Böhmer K, Hauner H, Philippen R, Gries FA: Successful insulin therapy in lipatrophic diabetes. Dtsch. med. Wschr. 116: 454-459, 1991
6. Boulware S D, Tamborlane W V, Rennert N J, Gesundheit N, Sherwin R S.: Comparison of the Metabolic Effects of Recombinant Human Insulin-like Growth Factor-I and Insulin. J. Clin. Invest. 93: 1131-1139, 1994
7. Chard T: Insulin-like Growth Factors and their Binding Proteins in Normal and Abnormal Human Fetal Growth. Growth & Regulation 4: 91-100, 1994
8. Corbin A., Upton GW, Mabry CC, et al.: Diencephalic involvement in generalized lipodystrophy: rationale and treatment with the neuroleptic agent pimozide. Acta Endocrinol. 77: 209-220, 1974
9. Daughaday WH, Hall K, Raben MS, Salmon WD, Brande van den JL, Wyk van JJ: Somatomedin: Proposed Designation for Sulphation Factor. Nature 235: 107, 1972
10. Daughaday WH, Mariz IK Blethen SL: Inhibition of access of bound somatomedin to membrane receptor and immuno-binding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 51: 781-788, 1980
11. Dills DG, Allen C, Palta M, Zaccaro J, Klein R, D'Allesio D: Insulin-Like Growth Factor-I Is Related to Glycemic Control in Children and Adolescents with Newly Diagnosed Insulin-Dependent Diabetes. J Clin Endocrinol Metab 80: 2139-2143, 1995
12. Furlanetto RW: Insulin-Like Growth Factor Measurements in the Evaluation of Growth Hormone Secretion. Horm Res 33: 25-30, 1990
13. Glick RP, Unterman TG: Radioimmunoassay of Insulin-like Growth Factors I and II in the Cerebrospinal Fluid of Patients with Pituitary and Other Central Nervous System Tumors. Neurosurgery 36: 556-564, 1995
14. Ishii DN: Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Research Reviews 20: 47-67, 1994
15. Kajimoto Y, Kawamori R, Fujitani Y, Kishimoto M, Kubato M, Yamasaki Y, Morishima T, Kamada T: A Case of Non-Insulin Dependent Diabetes Mellitus with Anti-insulin Antibody: Effect of subcutaneous Injection of Human Recombinant Insulin-like Growth Factor-I. Endocrine Journal 42: 101-105, 1995
16. Köbberling J: Genetic Syndromes Associated with Lipatrophic Diabetes. In: W Creutzfeld, J Köbberling, JV Neel. The genetics of diabetes mellitus. Springer-Verlag New York: 147-154, 1976
17. Lawrence RD: Lipodystrophy and hepatomegaly with diabetes, lipaemia. and other metabolic disturbances. Lancet I: 724-731, 1946
18. Louis LH, Conn JW, Minick MC: Lipoatrophic diabetes: isolation and characterization of an insulin antagonist from urine. Metabolism 12: 867-886, 1963
19. Magre J, Grigorescu F, Reynet C, et al.: Tyrosine-kinase defect of the insulin receptor in cultured fibroblasts from patients with lipoatrophic diabetes. J Clin Endocr. 69: 142-150, 1989
20. McCaleb ML, Izzo MS, Lockwood DH: Characterization and purification of a factor from human serum that induces insulin resistance. J Clin Invest 75: 391-396, 1985
21. Moller DE: Clinical Syndromes Associated with Insulin Resistance. In: D LeRoith, SI Taylor and JM Olefsky eds. Diabetes mellitus. Lippincott-Raven Publ. Philadelphia: 584-590, 1996
22. Rossini AA: Lipatrophic diabetes. In: Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS, eds Jolin's Diabetes mellitus. pages 834-842, Philadelphia: Lea and Febiger, 1985
23. Rutanen EM: Insulin-like growth factor binding protein-1 (Review). Seminars in Reprod Endocrinol 10: 154-163, 1992
24. Spiegelman BM and Hotamisligil GS: Through thick and thin: Wasting, obesity, and TNFα. Cell 73: 625-627, 1993
25. Stöcker W: Rationelle Histochemie mit einer neuen Mikroanalysemethode. Acta Histochem. 31: 269-281, 1985
26. Strasser-Vogel B, Blum W F, Past R, Kassler U, Hoeflich A. Meiler B, Kiess W. Insulin-Like Growth Factor (IGF)-I and -II and IGF-Binding Proteins-1, -2 and -3 in Children and Adolescents with Diabetes Mellitus: Correlation with Metabolic Control and Height Attainment. J Clin Endocrinol Metab. 80: 1207-1213, 1995
27. Upton GV, Corbin A: Hypothesis: Hypothalamic dysfunction and lipatrophic diabetes. Yale J Biol Med. 46: 314-323, 1973
28. Vestergaard H, Rossen M, Urhammer S, Müller J, Pedersen O: Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur. J. Endocrin. 136: 475-482, 1997
29. Vorm ER van der, Kuipers A, Bonekamp JW, et al.: Patients with lipodytrophic diabetes mellitus of the Seip-Berardinelli type express normal insulin receptors. Diabetologia 36: 172-174, 1993
30. Weimann E, Kiess W: Wachstumsfaktoren. Grundlagen und klinische Anwendung; mit 36 Tabellen. Mit einem Geleitw. von Peter Nissley. Stuttgart; New York: Schattauer, 49-84, 1995
31. Wilson TA, Alford BA, Morris L: Cerebral computed tomography in lipodystrophy. Arch Neurol. 39: 733, 1982
32. Zapf J: Walther H, Froesch ER: Radioimmunological determination of Insulin like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglygemia. J Clin Invest. 61; 1321-1330, 1981
33. Zenobi PD, Graf S, Ursprung H, Froesch ER. Effects of insulin-like growth factor-I on glucose tolerance, insulin-levels, and insulin secretion. J Clin Invest 89: 1908-1913, 1992